|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pollock PA, Ludgate A and Wassersug RJ: In
2124, half of all men can count on developing prostate cancer. Curr
Oncol. 22:10–12. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Litwin MS and Tan HJ: The diagnosis and
treatment of prostate cancer: A review. JAMA. 317:2532–2542. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sartor O and de Bono JS: Metastatic
prostate cancer. N Engl J Med. 378:645–657. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Leão R, Domingos C, Figueiredo A, Hamilton
R, Tabori U and Castelo-Branco P: Cancer stem cells in prostate
cancer: Implications for targeted therapy. Urol Int. 99:125–136.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gao J, Li W, Guo Y and Feng SS:
Nanomedicine strategies for sustained, controlled and targeted
treatment of cancer stem cells. Nanomedicine (Lond). 11:3261–3282.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gao J, Feng SS and Guo Y: Nanomedicine for
treatment of cancer stem cells. Nanomedicine (Lond). 9:181–184.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maitland NJ and Collins AT: Prostate
cancer stem cells: A new target for therapy. J Clin Oncol.
26:2862–2870. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Patrawala L, Calhoun T,
Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra
D, Zhou J, Claypool K, et al: Highly purified CD44+ prostate cancer
cells from xenograft human tumors are enriched in tumorigenic and
metastatic progenitor cells. Oncogene. 25:1696–1708. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gong Z, Chen D, Xie F, Liu J, Zhang H, Zou
H, Yu Y, Chen Y, Sun Z, Wang X, et al: Codelivery of salinomycin
and doxorubicin using nanoliposomes for targeting both liver cancer
cells and cancer stem cells. Nanomedicine (Lond). 11:2565–2579.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xie F, Zhang S, Liu J, Gong Z, Yang K,
Zhang H, Lu Y, Zou H, Yu Y, Chen Y, et al: Codelivery of
salinomycin and chloroquine by liposomes enables synergistic
antitumor activity in vitro. Nanomedicine (Lond). 11:1831–1846.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Naujokat C and Steinhart R: Salinomycin as
a drug for targeting human cancer stem cells. J Biomed Biotechnol.
2012:9506582012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang Y, Liu L, Li F, Wu T, Jiang H, Jiang
X, Du X and Wang Y: Salinomycin exerts anticancer effects on PC-3
cells and PC-3-derived cancer stem cells in vitro and in vivo.
Biomed Res Int. 2017:41016532017.PubMed/NCBI
|
|
14
|
Kim KY, Park KI, Kim SH, Yu SN, Park SG,
Kim YW, Seo YK, Ma JY and Ahn SC: Inhibition of autophagy promotes
salinomycin-induced apoptosis via reactive oxygen species-mediated
PI3K/AKT/mTOR and ERK/p38 MAPK-dependent signaling in human
prostate cancer cells. Int J Mol Sci. 18(pii): E10882017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hanrahan K, O'Neill A, Prencipe M, Bugler
J, Murphy L, Fabre A, Puhr M, Culig Z, Murphy K and Watson RW: The
role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in
mediating docetaxel-resistant prostate cancer. Mol Oncol.
11:251–265. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mirkheshti N, Park S, Jiang S, Cropper J,
Werner SL, Song CS and Chatterjee B: Dual targeting of androgen
receptor and mTORC1 by salinomycin in prostate cancer. Oncotarget.
7:62240–62254. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang M, Xie F, Wen X, Chen H, Zhang H, Liu
J, Zhang H, Zou H, Yu Y, Chen Y, et al: Therapeutic PEG-ceramide
nanomicelles synergize with salinomycin to target both liver cancer
cells and cancer stem cells. Nanomedicine (Lond). 12:1025–1042.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao J, Xia Y, Chen H, Yu Y, Song J, Li W,
Qian W, Wang H, Dai J and Guo Y: Polymer-lipid hybrid nanoparticles
conjugated with anti-EGF receptor antibody for targeted drug
delivery to hepatocellular carcinoma. Nanomedicine (Lond).
9:279–293. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wong HL, Rauth AM, Bendayan R, Manias JL,
Ramaswamy M, Liu Z, Erhan SZ and Wu XY: A new polymer-lipid hybrid
nanoparticle system increases cytotoxicity of doxorubicin against
multidrug-resistant human breast cancer cells. Pharm Res.
23:1574–1585. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao J, Chen H, Song H, Su X, Niu F, Li W,
Li B, Dai J, Wang H and Guo Y: Antibody-targeted immunoliposomes
for cancer treatment. Mini Rev Med Chem. 13:2026–2035. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guo X, Zhu X, Gao J, Liu D, Dong C and Jin
X: PLGA nanoparticles with CD133 aptamers for targeted delivery and
sustained release of propranolol to hemangioma. Nanomedicine
(Lond). 12:2611–2624. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kapoor DN, Bhatia A, Kaur R, Sharma R,
Kaur G and Dhawan S: PLGA: A unique polymer for drug delivery. Ther
Deliv. 6:41–58. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gao J, Feng SS and Guo Y: Antibody
engineering promotes nanomedicine for cancer treatment.
Nanomedicine (Lond). 5:1141–1145. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang J, Wu Z, Pan G, Ni J, Xie F, Jiang B,
Wei L, Gao J and Zhou W: Enhanced doxorubicin delivery to
hepatocellular carcinoma cells via CD147 antibody-conjugated
immunoliposomes. Nanomedicine. 16:1949–1961. 2018. View Article : Google Scholar
|
|
25
|
Zhou BB, Zhang H, Damelin M, Geles KG,
Grindley JC and Dirks PB: Tumour-initiating cells: Challenges and
opportunities for anticancer drug discovery. Nat Rev Drug Discov.
8:806–823. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen SH, Wang TF and Yang KL:
Hematopoietic stem cell donation. Int J Hematol. 97:446–455. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Billen A, Madrigal JA and Shaw BE: A
review of the haematopoietic stem cell donation experience: Is
there room for improvement? Bone Marrow Transplant. 49:729–736.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Auffan M, Rose J, Bottero JY, Lowry GV,
Jolivet JP and Wiesner MR: Towards a definition of inorganic
nanoparticles from an environmental, health and safety perspective.
Nat Nanotechnol. 4:634–641. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cushing BL, Kolesnichenko VL and O'Connor
CJ: Recent advances in the liquid-phase syntheses of inorganic
nanoparticles. Chem Rev. 104:3893–3946. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mamot C, Ritschard R, Wicki A, Stehle G,
Dieterle T, Bubendorf L, Hilker C, Deuster S, Herrmann R and
Rochlitz C: Tolerability, safety, pharmacokinetics, and efficacy of
doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid
tumours: A phase 1 dose-escalation study. Lancet Oncol.
13:1234–1241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Miller K, Cortes J, Hurvitz SA, Krop IE,
Tripathy D, Verma S, Riahi K, Reynolds JG, Wickham TJ, Molnar I and
Yardley DA: HERMIONE: A randomized Phase 2 trial of MM-302 plus
trastuzumab versus chemotherapy of physician's choice plus
trastuzumab in patients with previously treated,
anthracycline-naïve, HER2-positive, locally advanced/metastatic
breast cancer. BMC Cancer. 16:3522016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hrkach J, Von Hoff D, Mukkaram Ali M,
Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M,
Horhota A, et al: Preclinical development and clinical translation
of a PSMA-targeted docetaxel nanoparticle with a differentiated
pharmacological profile. Sci Transl Med. 4:128ra392012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cao H, Heazlewood SY, Williams B, Cardozo
D, Nigro J, Oteiza A and Nilsson SK: The role of CD44 in fetal and
adult hematopoietic stem cell regulation. Haematologica. 101:26–37.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cullion K, Draheim KM, Hermance N, Tammam
J, Sharma VM, Ware C, Nikov G, Krishnamoorthy V, Majumder PK and
Kelliher MA: Targeting the Notch1 and mTOR pathways in a mouse
T-ALL model. Blood. 113:6172–6181. 2009. View Article : Google Scholar : PubMed/NCBI
|
